JZJ(605266) Zheng Quan Zhi Xing·2025-06-11 12:35Core Viewpoint - The legal opinion from Beijing DeHeng Law Offices confirms that the differentiated dividend distribution plan of Jianzhijia Pharmaceutical Chain Group Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [6]. Group 1: Reasons for Differentiated Dividend - Jianzhijia held its sixth board meeting on June 20, 2024, approving a share repurchase plan using self-owned funds to maintain company value and shareholder rights, with 1,143,260 shares repurchased by the announcement date [2]. - A subsequent board meeting on September 19, 2024, approved another share repurchase plan, resulting in an additional 903,400 shares repurchased [4]. - On October 29, 2024, a third board meeting approved a plan to repurchase 4,338,200 shares, totaling 6,384,860 shares that will not participate in profit distribution [4]. Group 2: Differentiated Dividend Plan - The company plans to distribute a cash dividend of RMB 11.00 per 10 shares (including tax) based on the total share capital minus the repurchased shares, resulting in a total of 162,973,874.80 RMB to be distributed [5]. - The total share capital as of the legal opinion date is 154,542,928 shares, with 6,384,860 shares excluded from the distribution, leading to 148,158,068 shares participating in the dividend [5]. Group 3: Calculation Basis for Differentiated Dividend - The reference price for ex-dividend is calculated as approximately 22.0500 RMB per share, based on the closing price of 23.15 RMB minus the cash dividend [5]. - The virtual distribution calculation shows a minor impact on the ex-dividend reference price, estimated at approximately 0.2059% [5]. Group 4: Conclusion - The legal opinion concludes that the differentiated dividend distribution plan is in accordance with the Company Law, Securities Law, and relevant regulations, ensuring no detriment to the company or its shareholders [6].